[Skip to Content]
[Skip to Content Landing]
Views 67
Citations 0
Comment & Response
June 13, 2018

Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma

Author Affiliations
  • 1Kaiser Permanente, San Francisco, California
JAMA Dermatol. Published online June 13, 2018. doi:10.1001/jamadermatol.2018.1229

To the Editor Treatment with topical fluorouracil, 5%, compared with placebo reduced risk of surgically treated squamous cell carcinoma (SCC) and Mohs surgery for keratinocyte carcinoma (KC) for 1 year, according to a randomized clinical trial (RCT) report.1 However, because neither of these outcomes was prespecified, these findings should be interpreted very cautiously and should not sway clinical practice.

First Page Preview View Large
First page PDF preview
First page PDF preview
×